We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-0.49%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$312M
AUM Growth
+$302M
Cap. Flow
+$306M
Cap. Flow %
98.25%
Top 10 Hldgs %
48.33%
Holding
84
New
6
Increased
59
Reduced
1
Closed
18

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$30.2M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$25.2M
3
INCY icon
Incyte
INCY
+$20M
4
ALKS icon
Alkermes
ALKS
+$15.4M
5
GILD icon
Gilead Sciences
GILD
+$12.6M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.77M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$121K
3
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$107K
4
FOLD
Amicus Therapeutics
FOLD
+$94.6K
5
IMVT icon
Immunovant
IMVT
+$60K

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$28.2M 9.03%
454,973
+432,058
+1,885% +$30.2M
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$22.7M 7.29%
166,200
+154,593
+1,332% +$25.2M
INCY icon
3
Incyte
INCY
$25.9B
$19.3M 6.17%
289,000
+270,919
+1,498% +$20M
ALKS icon
4
Alkermes
ALKS
$8.22B
$13.2M 4.25%
593,000
+591,481
+38,939% +$15.4M
GILD icon
5
Gilead Sciences
GILD
$185B
$12.9M 4.13%
208,784
+199,772
+2,217% +$12.6M
BIIB icon
6
Biogen
BIIB
$32.7B
$12.1M 3.9%
45,500
+34,894
+329% +$7.41M
HRMY icon
7
Harmony Biosciences
HRMY
$2.32B
$11.7M 3.76%
264,500
+253,706
+2,350% +$12.4M
ITCI
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$10.3M 3.3%
221,856
+218,253
+6,058% +$11.4M
QURE icon
9
uniQure
QURE
$3.44B
$10.2M 3.27%
544,500
+536,182
+6,446% +$11.3M
SUPN icon
10
Supernus Pharmaceuticals
SUPN
$2.57B
$10.1M 3.23%
297,500
+288,896
+3,358% +$9.4M
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$9.5M 3.05%
136,000
+126,869
+1,389% +$9.39M
EXEL icon
12
Exelixis
EXEL
$13.7B
$8.51M 2.73%
543,000
+535,710
+7,349% +$10.4M
REGN icon
13
Regeneron Pharmaceuticals
REGN
$83.1B
$7.71M 2.47%
11,200
-2,810
-20% -$1.77M
ALNY icon
14
Alnylam Pharmaceuticals
ALNY
$31.6B
$7.6M 2.44%
38,000
+32,458
+586% +$6.19M
RARE icon
15
Ultragenyx Pharmaceutical
RARE
$2.59B
$7.2M 2.31%
174,052
+164,442
+1,711% +$8.45M
KDNY
16
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$6.68M 2.14%
340,389
+334,442
+5,624% +$6.71M
VERA icon
17
Vera Therapeutics
VERA
$2.5B
$5.99M 1.92%
281,257
+277,432
+7,253% +$5.19M
SNY icon
18
Sanofi
SNY
$107B
$5.46M 1.75%
143,500
+141,924
+9,005% +$6.32M
LKFT
19
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.93B
$5.25M 1.68%
123,300
+116,424
+1,693% +$5.97M
BMRN icon
20
BioMarin Pharmaceuticals
BMRN
$12.6B
$4.97M 1.59%
58,656
+52,055
+789% +$4.63M
ILMN icon
21
Illumina
ILMN
$34.3B
$4.77M 1.53%
25,700
+16,602
+182% +$3.28M
KALV
22
DELISTED
KalVista Pharmaceuticals
KALV
$4.59M 1.47%
316,133
+312,373
+8,308% +$4.37M
TVTX icon
23
Travere Therapeutics
TVTX
$6.37B
$4.58M 1.47%
186,019
+176,804
+1,919% +$4.57M
DYN icon
24
Dyne Therapeutics
DYN
$4.88B
$4.44M 1.42%
350,068
+346,203
+8,957% +$3.97M
AUPH icon
25
Aurinia Pharmaceuticals
AUPH
$2.19B
$4.31M 1.38%
573,530
+567,772
+9,861% +$4.91M
1
2 3 4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2022 Portfolio in Review

As of Q3 2022, International Biotechnology Trust held 84 positions worth $312M, up 3,153% from $9.59M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

International Biotechnology Trust deployed $306M of net new capital in Q3 2022, opening 6 new positions and adding to 59 existing holdings. Its largest new stake was Viatris: 364,000 shares worth $3.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $1.77M trimmed.

  • International Biotechnology Trust's largest Q3 2022 buy was Viatris: 364,000 shares worth $3.1M.
  • International Biotechnology Trust added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, an estimated $30.2M increase.
  • International Biotechnology Trust's biggest Q3 2022 reduction was Regeneron Pharmaceuticals, cutting an estimated $1.77M.
  • International Biotechnology Trust fully exited ChemoCentryx, Inc. in Q3 2022, selling an estimated $121K.
  • International Biotechnology Trust's ten largest holdings make up 48% of its $312M portfolio in Q3 2022.
  • International Biotechnology Trust opened 6 new positions and closed 18 in Q3 2022.
  • International Biotechnology Trust's portfolio value rose 3,153% quarter-over-quarter to $312M.

Based on International Biotechnology Trust's 13F filing for Q3 2022, filed 8 Nov 2022.